Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.

By D. Horn, D. Neofytos, E. Anaissie, J. Fishman, W. Steinbach, A. Olyaei, K. Marr, M. Pfaller, Chih Chang, K. Webster. Clinical Infectious Diseases, 2009

976 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/72a6e4d5ac401ed927dc22797db9c2eeba0640b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. J. Achkar
2. T. Walsh
3. B. Fries

In Infectious Diseases

1. J. Achkar
2. B. Fries
3. M. Pfaller
4. D. Diekema

Citations in the corpus

• Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “tality rates for invasive candidiasis in this setting are 30%–40% [167, 170].”
• Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. (2013, background): “C. albicans is the predominant cause of invasive fungal infections (Horn et al., 2009) and represents a serious public health challenge with increasing medical and economic importance due to the high mortality rates and increased costs of care and duration of hospitalization (Almirante et al.,…”
• Candida Infections of the Genitourinary Tract (2010, background): “albicans strains producing nosocomial infections (68, 118, 288).”